Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling

Cancer Letters

Volumn 307, Issue 2, 2011, Pages 200-210

  Han, Jinfeng ^a   Jogie Brahim, Sherryline ^a   Harada, Aki ^a   Oh, Youngman ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Apoptosis; Caspase; Chemodrug; IGFBP 3; NF B

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; CASPASE 8; DOXORUBICIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; SOMATOMEDIN BINDING PROTEIN 3; SYNAPTOTAGMIN I; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASES; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MICE; NF-KAPPA B; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIGNAL TRANSDUCTION;

EID: 79957653825     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.004     Document Type: Article

References (43)

1. Shishodia S., Aggarwal B.B. Nuclear factor-kappaB activation: a question of life or death. J. Biochem. Mol. Biol. 2002, 35:28-40.
2. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
3. Blat C., Delbe J., Villaudy J., Chatelain G., Golde A., Harel L. Inhibitory diffusible factor 45 bifunctional activity as a cell growth inhibitor and as an insulin-like growth factor I-binding protein. J. Biol. Chem. 1989, 264:12449-12454.
4. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., Budunova I.V. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 2002, 115:141-151.
5. Shukla S., Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin. Cancer Res. 2004, 10:3169-3178.
6. Suh J., Payvandi F., Edelstein L.C., Amenta P.S., Zong W.X., Gelinas C., Rabson A.B. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002, 52:183-200.
7. Lessard L., Mes-Masson A.M., Lamarre L., Wall L., Lattouf J.B., Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int. 2003, 91:417-420.
8. Huang S., Pettaway C.A., Uehara H., Bucana C.D., Fidler I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001, 20:4188-4197.
9. Takada Y., Kobayashi Y., Aggarwal B.B. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 2005, 280:17203-17212.
10. Chendil D., Ranga R.S., Meigooni D., Sathishkumar S., Ahmed M.M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004, 23:1599-1607.
11. Flynn Jr V., Ramanitharan A., Moparty K., Davis R., Sikka S., Agrawal K.C., Abdel-Mageed A.B. Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells. Int. J. Oncol. 2003, 23:317-323.
12. Chen C.D., Sawyers C.L. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell. Biol. 2002, 22:2862-2870.
13. Jogie-Brahim S., Feldman D., Oh Y. Unraveling IGFBP-3 actions in human disease. Endocr. Rev. 2009.
14. Valentinis B., Bhala A., DeAngelis T., Baserga R., Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol. Endocrinol. 1995, 9:361-367.
15. Buckway C.K., Wilson E.M., Ahlsen M., Bang P., Oh Y., Rosenfeld R.G. Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J. Clin. Endocrinol. Metab. 2001, 86:4943-4950.
16. Fanayan S., Firth S.M., Butt A.J., Baxter R.C. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J. Biol. Chem. 2000, 275:39146-39151.
17. Rajah R., Valentinis B., Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 1997, 272:12181-12188.
18. Lee K.W., Ma L., Yan X., Liu B., Zhang X.K., Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J. Biol. Chem. 2005, 280:16942-16948.
19. Jia Y., Lee K.W., Swerdloff R., Hwang D., Cobb L.J., Sinha Hikim A., Lue Y.H., Cohen P., Wang C. Interaction of insulin-like growth factor-binding protein-3 and BAX in mitochondria promotes male germ cell apoptosis. J. Biol. Chem. 2010, 285:1726-1732.
20. Butt A.J., Dickson K.A., Jambazov S., Baxter R.C. Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 2005, 146:3113-3122.
21. Williams A.C., Smartt H., H-Zadeh A.M., Macfarlane M., Paraskeva C., Collard T.J. Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ. 2007, 14:137-145.
22. Fulda S., Debatin K.M. Targeting apoptosis pathways in cancer therapy. Curr. Cancer Drug Targets 2004, 4:569-576.
23. Kim B.Y., Kim K.A., Kwon O., Kim S.O., Kim M.S., Kim B.S., Oh W.K., Kim G.D., Jung M., Ahn J.S. NF-kappaB inhibition radiosensitizes ki-ras-transformed cells to ionizing radiation. Carcinogenesis 2005, 26:1395-1403.
24. Yi H.K., Kim S.Y., Hwang P.H., Kim C.Y., Yang D.H., Oh Y., Lee D.Y. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochem. Biophys. Res. Commun. 2005, 330:760-767.
25. Forgues M., Marrogi A.J., Spillare E.A., Wu C.G., Yang Q., Yoshida M., Wang X.W. Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export pathway. J. Biol. Chem. 2001, 276:22797-22803.
26. Bae V.L., Jackson-Cook C.K., Maygarden S.J., Plymate S.R., Chen J., Ware J.L. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998, 34:275-282.
27. Hayward S.W., Dahiya R., Cunha G.R., Bartek J., Deshpande N., Narayan P. Establishment, characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev. Biol. 1995, 31:14-24.
28. Hayward S.W., Wang Y., Cao M., Hom Y.K., Zhang B., Grossfeld G.D., Sudilovsky D., Cunha G.R. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001, 61:8135-8142.
29. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
30. Chan J.M., Stampfer M.J., Ma J., Gann P., Gaziano J.M., Pollak M., Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. 2002, 94:1099-1106.
31. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., Stampfer M.J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 1999, 91:620-625.
32. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. 1999, 91:151-156.
33. Figueroa J.A., De Raad S., Tadlock L., Speights V.O., Rinehart J.J. Differential expression of insulin-like growth factor binding proteins in high versus low gleason score prostate cancer. J. Urol. 1998, 159:1379-1383.
34. Shariat S.F., Lamb D.J., Kattan M.W., Nguyen C., Kim J., Beck J., Wheeler T.M., Slawin K.M. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J. Clin. Oncol. 2002, 20:833-841.
35. Rhodes D.R., Barrette T.R., Rubin M.A., Ghosh D., Chinnaiyan A.M. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002, 62:4427-4433.
36. Gangadharan C., Thoh M., Manna S.K. Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J. Cell. Biochem. 2009, 107:203-213.
37. Calzado M.A., Bacher S., Schmitz M.L. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr. Med. Chem. 2007, 14:367-376.
38. Reuther J.Y., Baldwin A.S. Apoptosis promotes a caspase-induced amino-terminal truncation of IkappaBalpha that functions as a stable inhibitor of NF-kappaB. J. Biol. Chem. 1999, 274:20664-20670.
39. Kim K.W., Kim B.J., Chung C.W., Jo D.G., Kim I.K., Song Y.H., Kwon Y.K., Woo H.N., Jung Y.K. Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis. J. Cell. Biochem. 2002, 85:334-345.
40. Kim H.S., Chang I., Kim J.Y., Choi K.H., Lee M.S. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. Cancer Res. 2005, 65:6111-6119.
41. Kim H.S., Ingermann A.R., Tsubaki J., Twigg S.M., Walker G.E., Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 2004, 64:2229-2237.
42. Yamanaka Y., Fowlkes J.L., Wilson E.M., Rosenfeld R.G., Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999, 140:1319-1328.
43. Ingermann A.R., Yang Y.F., Han J., et al. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J. Biol. Chem. 2010, 285:30233-30246.